Testis conserving chemotherapy in germ cell cancer: Its potential to increase understanding of the biology and treatment of carcinoma-in-situ

APMIS

Volumn 111, Issue 1, 2003, Pages 86-92

  Oliver, R T D ^a   Ong, J ^a   Berney, D ^a   Nargund, V ^a   Badenoch, D ^a   Shamash, J ^a   Dieckmann, Klaus Peter ^b   Oliver, Tim ^b   Ahrens, Wolfgang ^b   Sharpe, Richard ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NONE

Author keywords

Chemotherapy; Conserving; Surgery; Testis

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; PLATINUM; VINBLASTINE;

BIOLOGY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CARCINOMA IN SITU; CONFERENCE PAPER; CONSERVATION BIOLOGY; DATA ANALYSIS; GERM CELL TUMOR; HUMAN; METASTASIS; ORCHIECTOMY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SAFETY; STATISTICAL SIGNIFICANCE; TESTIS CARCINOMA; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARCINOMA IN SITU; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; ORCHIECTOMY; TESTICULAR NEOPLASMS; TESTIS; TIME FACTORS; VINBLASTINE;

EID: 0037547070     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2003.11101121.x     Document Type: Conference Paper

References (46)

1. Oliver RTD. Atrophy, hormones, genes and viruses in aetiology of germ cell tumours. Cancer Surv 1990:263-8.
2. Oliver RTD. HLA phenotype and clinicopathological behaviour of germ cell tumours - possible evidence for clonal evolution from seminomas to nonseminomas. Int J Androl 1987;10:85-93.
3. Hoff Wanderas E, Fossa SD, Heilo A, Stenwig AE, Norman N. Serum Follicle Stimulating Hormone - Predictor of Cancer in the Remaining Testis in Patients with Unilateral Testicular Cancer. Br J Urol 1990;66:315-7.
4. Oliver RT, Ong J, Blandy JP, Altman DG. Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay, 1978-1994. Br J Urol 1996;78:119-24.
5. Heidenreich A, Weissbach L, Holtl W, Albers P, Kliesch S, Kohrmann KU, et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001;166:2161-5.
6. Ng R. The reproductive imperative: a case report highlighting the possibility of using chemotherapy to conserve the testis in patients with testis cancer. Clin Oncol 1997;9:334-7.
7. Oliver RTD, Dhaliwal HS, Hope-Stone HF, Blandy JP. Short course etoposide, bleomycin and cisplatin in the treatment of metastatic germ cell tumours. Appraisal of its potential as adjuvant chemotherapy for stage 1 testis tumours. Br J Urol 1988;61:53-8.
8. Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol 1998;81:884-8.
9. Oliver RTD, Love S, Ong J. Alternatives to radiotherapy in management of seminoma. Br J Urol 1990;65:61-7.
10. Ravi R, Oliver RT, Ong J, Badenoch DF, Fowler CG, Paris AM, et al. A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol 1997;80:647-52.
11. Oliver RTD, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 1992;148:1453-6.
12. Ravi R, Ong J, Oliver RTD. Long term follow up surveillance versus adjuvant chemotherapy treated stage 1 non-seminoma patients. J Urol 1998; 1998. p. abst 180.
13. Oliver RT, Edmonds PM, Ong JY, Ostrowski MJ, Jackson AW, Baille-Johnson H, et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol, Biol, Phys 1994;29:3-8.
14. Oliver RT, Boublikova L, Ong J. Fifteen Year Follow up of the Anglian Germ Cell Cancer Group Adjuvant Studies of Carboplatin as an Alternative to Radiation or Surveillance for Stage 1 Seminoma. Proc Amer Soc Clin Oncol 2001;20:197, abst. 780.
15. Nargund V, Lane T, Ong J, M.Cullen, Sohaib SA, Reznek RH, et al. Chemotherapy for Testis Conservation in Patients with Gern cell Cancer (GCC): Is it Safe and Could Combination with Tumour Enucleation Incease the Frequency of Success? In: Springer PH, editor. Germ Cell Tumours V. London, 2000:163-4.
16. Heidenreich A, Weissbach L. Bilateral germ cell cancer of the testis: a report of 11 patients with a long-term follow-up. BJU Int 2001;87:278-9.
17. Giannopoulos A. New data on the use of the potent immune stimulant interfron-gamma for the prevention of superficial bladder cancer recurrence. Br J Urol 2001;90 (Suppl. 2):140.
18. Hibi H, Yokoi K, Yamamoto M. Effects of alpha-interferon on sperm production, concentration, and motility in the rat. Int J Urol 1997;4:603-7.
19. Ku JH, Kim YH, Jeon YS, Lee NK. The preventive effect of systemic treatment with interferon-alpha2B for infertility from mumps orchitis. BJU Int 1999;84:839-42.
20. Udagawa K, Takeda M, Hosaka M, Kubota Y, Ogawa T. Recovery of spermatogenesis by high dose gonadotropin-releasing hormone analogue treatment in rat cryptorchid testis after orchiopexy. J Urol 1279;168:1279-83.
21. Yoshiji H, Kuriyama S, Fukui H. Perindopril: possible use in cancer therapy. Anticancer Drugs 2002;13:221-8.
22. Dieckmann KP, Loy V. Paternity in a patient with testicular seminoma and contralateral testicular intraepithelial neoplasia. Int J Androl 1993;16:143-6.
23. Petersen PM, Giwercman A, Hansen SW, Berthelsen JG, Daugaard G, Rørth M, et al. Impaired testicular function in patients with carcinoma-in-situ of the testis. J Clin Oncol 1999;17:173-9.
24. Jacobsen SDF, Bjoro TP, Ass N, Heilo A, Stenwig AE. Gonadal Function and Fertility in Patients with Bilateral Testicular Germ Cell Malignancy. Eur Urol 2002;42:229-38.
25. Jacobsen GK, Henriksen OB, von der Maase H. Carcinoma in-situ of testicular tissue adjacent to malignant germ cell tumours. A study of 105 cases. Cancer (Philadelphia) 1981;47:2260-2.
26. Christensen TB, Daugaard G, Geertsen P, H vdM. Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 1998;9:1-4.
27. Geldart TR, Simmonds PD, Mead GM. Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int 2002;90:451-5.
28. Greist A, Einhorn L, Williams S, Donohue J, Rowland R. Pathologic findings at orchidectomy following chemotherapy for disseminated testicular cancer. J Clin Oncol 1984;2:1025-7.
29. Chong C, Logothetis CJ, Voneschenbach A, Ayala A, Samuels M. Orchidectomy in advanced germ cell cancer following intensive chemotherapy - a comparison of systemic to testicular response. J Urol 1986;136:1221-3.
30. Leibovitch I, Little JS Jr., Foster RS, Rowland RG, Bihrle R, Donohue JP. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol 1996;155:952-4.
31. Skakkebæk N, Rajpert-DeMeyts E, Jorgensen N, Carlsen E, Petersen P, Giwercman A, et al. Germ cell cancer and disorders of spermatogensis: an environmental connection? APMIS 1998;106:3-11.
32. Rajpert-De Meyts E, Giwercman A, Skakkebæk NE. Carcinoma in-situ of the Testis - Precursor of Testicular Germ Cell Cancer: Biological and Clinical Aspects. Comprehensive Textbook of Genitourinary Oncology. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. 2000:897-908.
33. Oliver RTD, Leahy M, Ong J. Combined seminoma/non-seminoma should be considered as intermediate grade germ cell cancer (GCC). Eur J Cancer 1995;31A:1392-4.
34. Muller J, Skakkebæk NE. Microspectrophotometric DNA measurements of carcinoma-in-situ germ cells in the testis. Int J Androl 1981;4:211-21.
35. De Graaff WE, Oosterhuis JW, De Jong B, Dam A, Van Putten WLJ, Castedo SMMJ, et al. Ploidy of carcinoma in situ and invasive components of germ cell tumours of the testis. Lab Incest 1992;66:166-8.
36. Oosterhuis J, Castedo S, deJong B, Cornelisse C, Dam A, Sleijfer D, et al. Ploidy of primary germ cell tumors of the testis. Pathogenetic and clinical relevance. Lab Invest 1989;60:14-20.
37. Faulkner SW, Leigh DA, Oosterhuis JW, Roelofs H, Looijenga LH, Friedlander ML. Allelic losses in carcinoma in situ and testicular germ cell tumours of adolescents and adults: evidence suggestive of the linear progression model. British Journal of Cancer 2000;83:729-36.
38. Chaganti R, Rodriguez E, Mathew S. Origin of adult male mediastinal germ-free tumours. Lancet 1994;343:1130-2.
39. Chaganti RSK, Houldsworth J. The cytogenic theory of the pathogenesis of human adult male germ cell tumours. APMIS 1998;106:80-4.
40. Verkerk AJ, Ariel I, Dekker MC, Schneider T, van Gurp RJ, de Groot N, et al. Unique expression patterns of H19 in human testicular cancers of different etiology. Oncogene 1997;14:95-107.
41. Houldsworth J, Reuter V, Bosl GJ, Chaganti RS. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ 1997;8:293-9.
42. Zafarana G, Gillis AJ, van Gurp RJ, Olsson PG, Elstrodt F, Stoop H, et al. Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res 1822;62:1822-31.
43. Aubry F, Satie AP, Rioux-Leclercq N, Rajpert-De Meyts E, Spagnoli GC, Chomez P, et al. MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 2001;92:2778-85.
44. Satie AP, Rajpert-De Meyts E, Spagnoli GC, Henno S, Olivo L, Jacobsen GK, et al. The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Invest 2002;82:775-80.
45. Jorgensen N, Rajpert-De Meyts E, Graem N, Muller J, Giwercman A, Skakkebæk NE. Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. Lab Invest 1995;72:223-31.
46. Frank FE, Pauls K, Kerkman L. Angiotensin I-converting enzyme in testicular germ cell tumours. Hum Pathol 2000;31:1466-72.